Tag: Vivasc Therapeutics

Vivasc Therapeutics Inc. Receives Its Second NIH Phase I STTR Grant With the Goal of Reversing the Molecular Causes of Heart Failure

Coronary/Structural Heart by 0 comments

This approach may be a paradigm shift in patient care PITTSBURGH–(BUSINESS WIRE)–Vivasc Therapeutics Inc. is pleased to announce it has initiated its second NIH Phase I STTR research grant (Award Number R41HL164212), in conjunction with Georgetown University. This work is supported by the NIH National Heart, Lung, and Blood Institute, […]

Continue Reading →

Vivasc Therapeutics Inc. Receives NIH Phase I STTR Grant to Utilize Novel Cardiac Targeting Peptides for Targeted Delivery of Amiodarone to the Heart for Treatment of Atrial Fibrillation

Rhythm by 0 comments

This approach may minimize systemic toxicity associated with amiodarone PITTSBURGH–(BUSINESS WIRE)–The University of Pittsburgh and Vivasc Therapeutics Inc. today announced a research grant awarded by the NIH National Heart, Lung, and Blood Institute, valued at approximately $327,000 for the continued development of CTP-amio, the company’s lead compound, for the treatment […]

Continue Reading →